Lindbrook Capital »

Dianthus Therapeutics shares owned by Lindbrook Capital

Quarter-by-quarter ownership of Dianthus Therapeutics (DNTH) shares owned by Lindbrook Capital from 13F filings

Historical chart of Lindbrook Capital investment in Dianthus Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Dianthus Therapeutics held by Lindbrook Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Dianthus Therapeutics by Lindbrook Capital

Quarter filed Position value Share count Share price at filing
2024-12-31 $457 21 21.81
2024-09-30 $464 17 27.35

More positions owned by Lindbrook Capital

Vanguard Total Stk Mkt Etf (VTI)
Vanguard Total Intl Stock Idex Etf Etf (VXUS)
Apple Stock (AAPL)
Spdr S&p 500 Etf Trust Etf (SPY)
Golub Cap Bdc Cef (GBDC)
Ishares Russell 1000 Growth Etf Etf (IWF)
Nvidia Corporation Stock (NVDA)
Microsoft Stock (MSFT)
Rpar Risk Parity Etf Etf (RPAR)
Amazon.com Stock (AMZN)
Broadcom Stock (AVGO)
Ishares Russell 1000 Value Etf Etf (IWD)
Powershares Qqq Tr Etf (QQQ)
Google Stock (GOOGL)
Vanguard Growth Etf Etf (VUG)

View all positions for Lindbrook Capital

Top funds holding Dianthus Therapeutics

FMR
Avidity Partners Management
Fairmount Funds Management
Bain Capital Life Sciences Investors
Octagon Capital Advisors
RA Capital Management
VR Adviser
BlackRock
TCG Crossover Management
Vanguard Group
Braidwell
Alliancebernstein
Henderson Group
5AM Venture Management
State Street Corporation

View all funds holding Dianthus Therapeutics